Regular ArticleContinuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine
References (90)
- et al.
Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X
Lancet
(1995) - et al.
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukaemia
Blood
(1998) - et al.
Purification of hypoxanthine-guanine phosphoribosyltransferase of Plasmodium lophurae
Mol Biochem Parasitol
(1987) - et al.
Metabolic effects of thiopurine derivatives against human CCRF-CEM leukaemia cells
Int J Biochem Cell Biol
(1998) - et al.
Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukaemia
Leukaemia Res
(1992) - et al.
Reversal of methylmercaptopurine cytotoxicity by purine ribonucleotides and adenine
Biochem Pharmacol
(1995) - et al.
The cytotoxicity of thioguanine versus mercaptopurine in acute lymphoblastic leukaemia
Leukaemia Res
(1994) - et al.
Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukaemic T-lymphocytes
Biochem Pharmacol
(1996) - et al.
Desulfuration of 6-mercaptopurine: The basis for the paradoxical cytotoxicity of thiopurines in cultured human leukaemic cells
Biochem Pharmacol
(1993) - et al.
The cytotoxicity of thioguanine versus mercaptopurine in acute lymphoblastic leukaemia
Leukaemia Res
(1994)
Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukaemic blasts from children with acute lymphoblastic leukaemia
Blood
(1995)
Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines
J Biol Chem
(1991)
Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphoblastic leukaemia and is associated with decreased reduced folate carrier expression
Blood
(1997)
Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukaemia in children
Blood
(1997)
Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukaemia: A pilot prognostic factor analysis
Blood
(1990)
Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukaemia: a Pediatric Oncology Group Study
Blood
(1992)
Reduced folate carrier expression in acute lymphoblastic leukaemia, a mechanism for pliody but not lineage differences in methotrexate accumulation
Blood
(1999)
Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukaemic cells in vitro by methotrexate
Biochem Pharmacol
(1998)
Dose-dependent kinetics of orally administered6-mercaptopurine in children with leukaemia
J Pediatrics
(1991)
Pharmacokinetics and pharmacodynamics of methotrextare and mercaptopurine in children with lower risk acute lymphoblastic leukaemia: A joint Children's Cancer Group and Pediatric Oncology Branch study
Blood
(1998)
Studies of sequential and combination antimetabolite therapy in acute leukaemia: 6-mercaptopurine and methotrexate
Blood
(1961)
The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute leukaemia: A model for evaluation of other potentially useful therapy
Blood
(1963)
The effectivess of combinations of antileukaemic agents in inducing and maintaining remission induction in children with acute leukaemia
Blood
(1965)
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukaemia
Blood
(1999)
The relationship between thiopurine methyltransferase activity and genotype in blasts form patients with acute leukaemia
Blood
(1998)
Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukaemia
Leukaemia Res
(1992)
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lancet
(1990)
Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia
Lancet
(1994)
Studies of sequential and combination antimetabolite therapy in acute leukaemia: 6-mercaptopurine and methotrexate
Blood
(1961)
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
Lancet
(1998)
Optimal current treatment of childhood acute lymphoblastic leukaemia
Cancer Treat Rep
(1981)
Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukaemia: a report of the CCG-161 study by the Children's Cancer Study Group
J Clin Oncol
(1991)
High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukaemia: Results of protocol ALL VI form the Dutch Childhood Leukaemia Study Group
J Clin Oncol
(1996)
Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukaemia: A Pediatric Oncology Group Phase III trial
J Clin Oncol
(1998)
Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukaemia; a Pediatric Oncology Group study
J Clin Oncol
(1994)
Augmented post-induction therapy for children with high-risk acute lymphoblastic leukaemia and a slow response to initial therapy
N Engl J Med
(1998)
Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood)
Br J Haematol
(1991)
The purine path to chemotherapy
Science
(1989)
Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues
Cancer Res
(1984)
Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase
Mol Pharmacol
(1995)
Inhibition of phosphoribosyl pyrophosphate amidotransferase form Erlich ascites-tumour cells by thiopurine nucleotides
Biochem Pharmacol
(1968)
Purine antimetabolites
Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines
Cancer Res
(1985)
Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase and endonuclease function
Mol Pharmacol
(1992)
The role of DNA mismatch repair in drug resistance
Clin Cancer Res
(1998)
Cited by (0)
- f1
Correspondence to: Dr E. J. Estlin, Department of Paediatric Oncology, Royal Manchester Children's Hospital, Pendlebury, Manchester M27 4HA, UK, Tel.: 01617272950; Fax: 01617283529; E-mail:[email protected]
Copyright © 2001 Harcourt Publishers Ltd. All rights reserved.